Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma

Modern Pathology

Volumn 18, Issue 5, 2005, Pages 705-709

  Lin, Lin ^a   Hicks, David ^a   Xu, Bo ^a   Sigel, Jessica E ^a   Bergfeld, Wilma F ^a   Montgomery, Elizabeth ^b   Fisher, Cyril ^c   Hartke, Marybeth ^a   Tubbs, Raymond ^a   Goldblum, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cyclin D1 protein expression; Epithelioid sarcoma; Gene amplification; mRNA expression

Indexed keywords

CYCLIN D1; MESSENGER RNA;

ADULT; AGED; ARTICLE; CHROMOSOME 11Q; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DATA ANALYSIS; EPITHELIOID SARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MANTLE CELL LYMPHOMA; MOLECULAR GENETICS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SOFT TISSUE TUMOR;

CYCLIN D1; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RNA, MESSENGER; SARCOMA; U937 CELLS;

EID: 21044450489     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800349     Document Type: Article

References (37)

1. Enzinger FM. Epithelioid sarcoma. A sarcoma simulating a granuloma or a carcinoma. Cancer 1970;26: 1029-1041.
2. Weiss SW, Goldblum JR, In: Soft Tissue Tumors. Mosby, Inc.: Marc Strauss, St Louis, 2001, 1532pp.
3. Chase DR, Enzinger FM. Epithelioid sarcoma. Diagnosis, prognostic indicators, and treatment. Am J Surg Pathol 1985;9:241-263.
4. Miettinen M, Fanburg-Smith JC, et al. Epithelioid sarcoma: an immunohistologic analysis of 112 classical and variant cases and a discussion of the differential diagnosis. Hum Pathol 1999;30:934-942.
5. Lushnikova T, Knuutila S, Miettinen M. DNA copy number changes in epithelioid sarcoma and its variants: a comparative genomic hybridization study. Mod Pathol 2000;13:1092-1096.
6. Matsushime H, Roussel MF, Ashmun RA, et al. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 1991; 65:701-713.
7. Matsushime H, Quelle DE, Shurtleff SA, et al. D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 1994;14:2066-2076.
8. Baldin V, Lukas J, Marcote MJ, et al. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993;7:812-821.
9. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-555.
10. Weisenburger DD, Armitage JO. Mantle cell lymphoma - an entity comes of age. Blood 1996;87:4483-4494.
11. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-127.
12. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-560.
13. Jares P, Rey MJ, Fernandez PL, et al. Cyclin D1 and retinoblastoma gene expression in human breast carcinoma: correlation with tumour proliferation and oestrogen receptor status. J Pathol 1997;182:160-166.
14. Guo SS, Wu X, Shimoide AT, et al. Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours. J Endocrinol 2003;179:73-79.
15. Chung DC, Brown SB, Graeme-Cook F, et al. Overexpression of cyclin D1 occurs frequently in human pancreatic endocrine tumors. J Clin Endocrinol Metab 2000;85:4373-4378.
16. Kim SH, Lewis JJ, Brennan MF, et al. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 1998;4: 2377-2382.
17. Kim SH, Cho NH, Tallinl G, et al. Prognostic role of cyclin D1 in retroperitoneal sarcomas. Cancer 2001;91: 428-434.
18. Kennedy MM, Biddolph S, Lucas SB, et al. Cyclin D1 expression and HHV8 in Kaposi sarcoma. J Clin Pathol 1999;52:569-573.
19. Maelandsmo GM, Berner JM, Florenes VA, et al. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 1995;72:393-398.
20. Antonescu CR, Leung DH, Dudas M, et al. Alterations of cell cycle regulators in localized synovial sarcoma: a multifactorial study with prognostic implications. Am J Pathol 2000;156:977-983.
21. Frater JL, Tsiftsakis EK, Hsi ED, et al. Use of novel t(11;14) and t(14;18) dual-fusion fluorescence in situ hybridization probes in the differential diagnosis of lymphomas of small lymphocytes. Diagn Mol Pathol 2001;10:214-222.
22. Vaziri SA, Tubbs RR, Darlington G, et al. Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 2001;54:259-263.
23. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 1996;68:67-108.
24. Sola B, Salaun V, Ballet JJ, et al. Transcriptional and post-transcriptional mechanisms induce cyclin-D1 over-expression in B-chronic lymphoproliferative disorders. Int J Cancer 1999;83:230-234.
25. Bartkova J, Lukas J, Strauss M, et al. Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 1995;10:775-778.
26. Lavoie JN, L'Allemain G, Brunet A, et al. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 1996;271:20608-20616.
27. Lee RJ, Albanese C, Stenger RJ, et al. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 1999;274:7341-7350.
28. Gille H, Downward J. Multiple ras effector pathways contribute to G(1) cell cycle progression. J Biol Chem 1999;274:22033-22040.
29. Diehl JA, Cheng M, Roussel MF, et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998;12: 3499-3511.
30. Muise-Helmericks RC, Grimes HL, Bellacosa A, et al. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway. J Biol Chem 1998;273:29864-29872.
31. Guo Y, Stacey DW, Hitomi M. Post-transcriptional regulation of cyclin D1 expression during G2 phase. Oncogene 2002;21:7545-7556.
32. Choi YH, Lee SJ, Nguyen P, et al. Regulation of cyclin D1 by calpain protease. J Biol Chem 1997;272: 28479-28484.
33. Hashemolhosseini S, Nagamine Y, Morley SJ, et al. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998;273:14424-14429.
34. Langenfeld J, Kiyokawa H, Sekula D, et al. Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 1997;94:12070-12074.
35. Jefferies HB, Fumagalli S, Dennis PB, et al. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J 1997;16:3693-3704.
36. Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, et al. Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 1993;13:7358-7363.
37. Welcker M, Lukas J, Strauss M, et al. Enhanced protein stability: a novel mechanism of D-type cyclin overabundance identified in human sarcoma cells. Oncogene 1996;13:419-425.